AtriCure (ATRC)

• Market cap: $1.87B
• 1 day: 2.21%
• 5 days: 16.33%
• 1 month: 22.13%
• 3 months: 34.65%
• 6 months: 53.45%
• Year to date: 26.55%
• 1 year: 15.15%
• 5 years: 0.58%
• 10 years: 86.21%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Employees: 1,200

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

308% more call options, than puts

Call options by funds: $824K | Put options by funds: $202K

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

19% more capital invested

Capital invested by funds: $1.17B [Q2] → $1.39B (+$217M) [Q3]

17% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 35

2% more funds holding

Funds holding: 195 [Q2] → 198 (+3) [Q3]

4.67% less ownership

Funds ownership: 106.19% [Q2] → 101.53% (-4.67%) [Q3]

24% less repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 75

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $36 6% downside
• Avg. target: $43 11% upside
• High target: $61 59% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

Needham Mike Matson 52% 1-year accuracy 64 / 122 met price target	4% upside $40	Buy Reiterated	13 Jan 2025
JP Morgan Lilia-Celine Lozada 100% 1-year accuracy 1 / 1 met price target	4% upside $40	Overweight Assumed	17 Dec 2024
Canaccord Genuity William Plovanic 72% 1-year accuracy 34 / 47 met price target	59% upside $61	Buy Maintained	9 Dec 2024
Oppenheimer Suraj Kalia 61% 1-year accuracy 14 / 23 met price target	6% downside $36	Outperform Maintained	30 Oct 2024
JP Morgan Robbie Marcus 62% 1-year accuracy 13 / 21 met price target	4% upside $40	Overweight Maintained	30 Oct 2024